Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA)
Giuseppe Argenziano,Francesco Cusano,Monica Corazza,Salvatore Amato,Paolo Amerio,Luigi Naldi,Cataldo Patruno,Paolo D Pigatto,Pietro Quaglino,Paolo Gisondi,Andrea Chiricozzi,Francesco Tonon,Luca Stingeni,Piergiacomo Calzavara-Pinton,Andreas Wollenberg,Maria Kinberger,Bernd W Arents,Nora Aszodi,Gabriela L Avila Valle,Sebastien Barbarot,Thomas Bieber,Helen A Brough,Stéphanie Christen-Zäch,Mette Deleuran,Martin Dittmann,Corinna Dressler,Antjie H Fink-Wagner,Nicole Fosse,Krisztián Gáspár,Louise A Gerbens,Uwe Gieler,Giampiero Girolomoni,Stamatios Gregoriou,Charlotte G Mortz,Alexander Nast,Uffe Nygaard,Magali Redding,Eva M Rehbinder,Johannes Ring,Mariateresa Rossi,Esther Serra-Baldrich,Dagmar Simon,Zsuzsanna Z Szalai,Jacek C Szepietowski,Antonio Torrelo,Thomas Werfel,Carsten Flohr
DOI: https://doi.org/10.23736/S2784-8671.24.07664-3
Abstract:SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis. With the permission of EuroGuiDerm, SIDeMaST adapted the guideline to the Italian healthcare context to supply a reliable and affordable tool to Italian physicians who take care of patients affected by atopic dermatitis. The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. Twenty-nine experts (including clinicians and patient representatives) from 12 European countries participated. This first part of the guideline includes general information on its scope and purpose, the health questions covered, target users and a methods section. It also provides guidance on which patients should be treated with systemic therapies, as well as recommendations and detailed information on each systemic drug. The systemic treatment options discussed in the guideline comprise conventional immunosuppressive drugs (azathioprine, ciclosporin, glucocorticosteroids, methotrexate and mycophenolate mofetil), biologics (dupilumab, lebrikizumab, nemolizumab, omalizumab and tralokinumab) and janus kinase inhibitors (abrocitinib, baricitinib and upadacitinib). Part two of the guideline will address avoidance of provocation factors, dietary interventions, immunotherapy, complementary medicine, educational interventions, occupational and psychodermatological aspects, patient perspective and considerations for pediatric, adolescent, pregnant and breastfeeding patients.